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tial dosimetric information. It allows an accurate, systematic numerical 
and patient-speciﬁc study of the relationship between RT-induced ﬁbro-
sis and local dose. Very good correlations were obtained between local 
MC doses and the probability of RT-induced ﬁbrosis. The methodology 
presented in this paper may have important implications in future dose 
escalation studies. 
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Background: Stereotactic radiotherapy (SRT) using 4-dimensional 
(4D) target deﬁnition for NSCLC has been performed at the VU Uni-
versity Medical Center since April 2003. Patients with Stage I NSCLC 
who were medically unﬁt for surgery or refused such treatment were 
eligible for SRT. Patients were closely followed-up using a standard 
schedule of up to four follow-up CT scans in the two years following 
SRT. Outcomes in the ﬁrst 197 patients with 210 primary lung tumors 
were analyzed.
Methods: The group consisted of 164 medically inoperable patients 
and 33 who refused surgery. The median age was 73 years, and 154 
T1 tumors (73%) and 56 T2 tumors (27%) were treated. Pre-treatment 
histological conﬁrmation of malignancy was obtained in 61 patients 
(31%). The other patients had new and/or growing, PET-positive le-
sions (a previous randomised study in our region had revealed that the 
incidence of benign lesions in such a situation was less than 5%). In-
dividualized internal target volumes (ITV) were generated by contour-
ing maximum-intensity projections from 4DCT scans. Planning target 
volumes (PTV) were derived by adding a 3 mm margin to the ITV to 
account for residual patient setup errors using the Novalis Exactrac on-
line setup procedure. SRT was delivered using 8-12 non-coplanar static 
beams. Fractionation schemes were 3x20 Gy (n=86) for T1 tumors, 
5x12 Gy (n=97) for either T1 tumors adjacent to the thoracic wall/me-
diastinum or T2 tumors, and 8x7.5 Gy (n=27) for lesions adjacent to 
the pericardium or hilus, all prescribed at the 80% isodose. 
Results: Median overall survival was 34 months, with actuarial overall 
survival of 79% and 63% at 1 and 2 years, respectively. Follow-up 
imaging showed local failures in 6 patients (no histological conﬁrma-
tion), resulting in an actuarial local failure-free survival rate of 94% 
at two years. Despite a pre-treatment FDG-PET in all but 3 patients, 
regional failure was observed in 16 patients at a median interval of 7 
months. The actuarial regional failure-free survival at 1 and 2 years 
was 94% and 85%. Regional recurrences were located in the ipsilateral 
hilus (n=4), the mediastinum (n=6), or both (n=6). Distant failure free 
survival rates at 1 and 2 years were 86% and 79%, respectively. Overall 
and disease-free survival was not signiﬁcantly different in patients with 
or without histological conﬁrmation of malignancy (Figure 1). Out-
comes in stage IB disease were worse than in stage IA for both overall 
(p=0.02) and disease-free survival (p=0.04) (Figure 2). 
Early toxicity was mild, with fatigue (32%), nausea (10%), and chest 
pain (8%) being the most frequently reported. Late toxicity was un-
common, with grade ≥3 radiation pneumonitis in 6 patients (3%). Rib 
fractures and chronic chest wall pain syndromes were observed in 3 
patients each. 
Conclusions: Local control rates of ≥90% are achieved using SRT, 
making it an effective alternative to surgery in patients who are margin-
ally ﬁt for operation or refusing surgery. The incidence of severe early 
or late toxicity is low. As was also reported following surgery, regional 
and/or distant failure is the most common pattern of relapse in stage I 
NSCLC despite pre-treatment FDG-PET scans.
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Background: Stereotactic-body-radiotherapy (SBRT) is a treatment 
regime for Stage I lung cancer patients showing very high local control 
rates. To limit toxicity, treatment volumes need to be minimized requir-
ing high precision treatment techniques. We propose the use of four 
dimensional (4D) cone beam CT (CBCT) guidance to minimize treat-
ment delivery errors.
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Methods: Patients with peripheral tumors ≤ 5 cm are treated with 
SBRT without body frame to 54 Gy in 3 fractions within 8-10 days. 
For treatment planning, a 4DCT reference scan is acquired representing 
the patients anatomy over the breathing cycle. From this 4D dataset, a 
single 3D frame is extracted with the tumor and surrounding anatomy 
in their time averaged mean position. The Planning-Target-Volume 
(PTV)-margins depend on the patient speciﬁc tumor amplitude. Or-
gans-at-risk (OAR) are delineated and automatically expanded by 1 cm 
to validate that corrections up to 1 cm during treatment delivery can be 
safely executed without violating ﬁxed dose constraints. Before each 
treatment fraction, the linac integrated CBCT scanner is used to acquire 
a new 4D data set (Figure 1a). A local rigid registration technique is 
used to measure the tumor trajectory after which the time averaged 
tumor misalignment is calculated and corrected with a couch shift. At 
the end of the treatment fraction another 4D-CBCT scan is acquired to 
determine intrafraction stability. 
Results: So far 34 patients have been treated with SBRT in our institu-
tion. Residual treatment delivery inaccuracies were analyzed for the 
ﬁrst 20 patients. Based on these results, the required PTV-margin were 
calculated to account for delineation uncertainties (2 mm SD in each 
direction), breathing motion, residual setup errors and intrafraction 
baseline variation (both ≤ 2 mm (1 SD) systematic and random) as 
shown in Figure 1b. For example at a 1 cm tumor amplitude, a total 
margin of only 0.7 cm is required. Compared to a bony anatomy driven 
correction protocol combined with an Internal-Target-Volume (ITV) 
approach to account for respiratory motion this is a 49% reduction. 
For all patients, tumor-to-bony anatomy discrepancies never exceeded 
1 cm and post treatment validation scans did not show unacceptable 
deviations.
Conclusion: SBRT without body frame can be safely administered us-
ing 4D-CBCT guidance. Even with considerable breathing motion the 
PTV-margins can safely be kept relatively small allowing patients with 
larger tumor volumes to beneﬁt from the advantages of SBRT.
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Background: Platinum-based CT-RT improves survival in stage III 
NSCLC compared to RT, although with increased toxicity. Drug doses 
in most concurrent schemes are suboptimal for systemic activity, and 
full dose induction or consolidation CT appears advantageous. Some 
trials had suggested that induction CT followed by concurrent RT was 
not superior to concurrent RT followed by consolidation CT. Docetaxel 
(D) is active in NSCLC, has radiosensitising effect and is promising 
when given as consolidation agent. 
Aim: Randomised phase 2 trial comparing the toxicity/safety and 
efﬁcacy of CT followed by CT-RT (IND) vs. CT-RT followed by CT 
(CON).
Methods: Eligible pts had unresectable stage III NSCLC and WHO 
PS 0-1, weight loss ≤10%, adequate renal, pulmonary, haematologi-
cal and hepatic function. Induction and consolidation CT consisted of 
D 75 mg/m2 on d1 and cisplatin (C) 40 mg/m2 on d1&2, both q3 wks 
for 2 cycles. CT-RT consisted of D 20 mg/m2 and C 20 mg/m2 both 
given on d1 weekly for 6 wks, concurrent with 66 Gy (2 Gy/d, 5 d/w 
for 6.5 wks). Toxicity was reduced using the following approaches: 1. 
Involved ﬁelds using 3D treatment planning; 2: exclusion of pts with 
V20 values >35 Gy from immediate concurrent CT-RT by cross-over 
to IND and treatment to a post-CT tumor volume. Toxicity/response 
was evaluated according to NCI-CTC/RECIST. With a type 1 error 
of 0.2, a power of 0.8 and allowing for 15% cross-over or ineligibil-
ity, a 70-pts sample size is needed to conﬁdently exclude a grade 3-4 
oesophageal toxicity rate of >25% in either arm. Toxicity and response 
were based upon actual treatment received; outcome is estimated in the 
ITT population.
Results: 70 patients with the following characteristics were enrolled: 
IND: 36/CON: 34; male (%): IND 75/CON 91; median age 61 y; 
squamous ca (%): IND 31; CON: 50; IIIB(%): IND 44/CON 68; PTV 
(cc): IND 288/CON 283. 5 pts switched from CON to IND. Treatment, 
response and toxicity data according to actual treatment received are in 
the table. ITT 1-year overall and progression free survival (PFS) rates 
(± 95% CI) are 56% ± 16% and 36% ± 16% for IND and 65% ± 17% 
and 53% ± 17% for CON (p =0.8 and 0.3)
Conclusions: Both IND and CON approaches have similar treatment 
intensity and duration, similar esophageal toxicity rates and comparable 
response rates. CON results in a trend towards a better PFS at the cost 
of a higher haematological toxicity. 
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Figure 1: a) Coronal slices of three frames of a 4D-CBCT scan acquired just prior to SBRT 
treatment. Despite some artifacts, tumor motion and accurate alignment can be easily 
verified.  b) Cranial-caudal GTV-to-PTV margin (no CTV margin used) required to account 
for delineation uncertainties, breathing motion, residual setup error and intrafraction 
variability as a function of tumor peak-to-peak amplitude: using 4D-CBCT guidance 
compared to a bony anatomy driven protocol combined with an ITV approach. Even at 
large tumor amplitudes margins are relatively small due to accurate guidance, shallow
penumbra in lung and dose prescription to relative low iso-doses (typically 70% to 80%).
